Madrigal pharmaceuticals announces new data from the phase 3 maestro-nash study of rezdiffra™ (resmetirom) presented at the easl congress

Conshohocken, pa., june 06, 2024 (globe newswire) -- madrigal pharmaceuticals, inc. (nasdaq:mdgl), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (nash), today announced results from new analyses of the phase 3 maestro-nash trial of rezdiffra being presented at the easl congress, which takes place from june 5-8, 2024 in milan, italy.
MDGL Ratings Summary
MDGL Quant Ranking